IGC Pharma (IGC) Income towards Parent Company (2010 - 2025)
IGC Pharma (IGC) posted quarterly Income towards Parent Company of -$1.8 million for Q3 2025, down 6.06% year-over-year from -$1.9 million in Q3 2024, and down 13.88% quarter-over-quarter from -$1.6 million in Q2 2025.
IGC Pharma (IGC) Income towards Parent Company (2010 - 2025) Analysis & Trends
IGC Pharma (IGC) has reported Income towards Parent Company for 16 consecutive years, with -$1.8 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Income towards Parent Company fell 6.06% year-over-year to -$1.8 million; the TTM figure through Mar 2026 stood at -$3.4 million (up 51.98% YoY), while the FY2026 annual figure was -$2.4 million, up 50.12% from the prior year.
- Income towards Parent Company fell to -$1.8 million in Q3 2025 per IGC's latest filing, from -$1.6 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at -$1.2 million in Q1 2025 and bottomed at -$6.6 million in Q1 2022.
- Historically, Income towards Parent Company has averaged -$2.7 million across 5 years, with a median of -$2.4 million in 2024.
- Annual changes were most pronounced in 2021 — Income towards Parent Company plunged 4173.91% — and 2023, when it soared 75.37%.
- IGC Pharma's Income towards Parent Company stood at -$2.4 million in 2021, then gained by 5.54% to -$2.2 million in 2022, then slumped by 148.51% to -$5.6 million in 2023, then surged by 67.28% to -$1.8 million in 2024, then climbed by 0.44% to -$1.8 million in 2025.
- Business Quant data shows IGC's Income towards Parent Company at -$1.8 million in Q3 2025, -$1.6 million in Q2 2025, and -$1.2 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | IGC Pharma | 30.17 Mn | 29.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -1.82 Mn |
| Jun 30, 2025 | -1.60 Mn |
| Mar 31, 2025 | -1.20 Mn |
| Dec 31, 2024 | -1.83 Mn |
| Sep 30, 2024 | -1.72 Mn |
| Jun 30, 2024 | -2.38 Mn |
| Mar 31, 2024 | -4.36 Mn |
| Dec 31, 2023 | -5.59 Mn |
| Sep 30, 2023 | -2.45 Mn |
| Jun 30, 2023 | -2.08 Mn |
| Mar 31, 2023 | -1.61 Mn |
| Dec 31, 2022 | -2.25 Mn |
| Sep 30, 2022 | -2.44 Mn |
| Jun 30, 2022 | -2.79 Mn |
| Mar 31, 2022 | -6.55 Mn |
| Dec 31, 2021 | -2.38 Mn |
| Sep 30, 2021 | -4.34 Mn |
| Jun 30, 2021 | -1.79 Mn |
| Mar 31, 2021 | -2.95 Mn |
| Dec 31, 2020 | -2.32 Mn |